Results 241 to 250 of about 1,349,968 (301)

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

A Stochastic Cluster Expansion for Electronic Correlation in Large Systems. [PDF]

open access: yesJ Phys Chem Lett
Canestraight A   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy